King Luther Capital Management Corp Decreases Stock Position in Zoetis Inc. $ZTS

King Luther Capital Management Corp cut its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 23.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,044,463 shares of the company’s stock after selling 312,766 shares during the period. King Luther Capital Management Corp owned approximately 0.24% of Zoetis worth $152,826,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in shares of Zoetis by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 42,306,764 shares of the company’s stock worth $6,190,326,000 after purchasing an additional 419,777 shares during the period. Geode Capital Management LLC grew its holdings in Zoetis by 0.9% during the second quarter. Geode Capital Management LLC now owns 11,081,301 shares of the company’s stock valued at $1,721,356,000 after purchasing an additional 95,294 shares during the period. Norges Bank purchased a new stake in Zoetis in the second quarter worth about $809,491,000. Brown Advisory Inc. raised its stake in shares of Zoetis by 5.7% in the second quarter. Brown Advisory Inc. now owns 4,659,371 shares of the company’s stock worth $726,629,000 after buying an additional 250,829 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Zoetis by 113.0% during the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock valued at $586,671,000 after buying an additional 1,995,491 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 2.9%

Shares of ZTS stock opened at $129.17 on Thursday. Zoetis Inc. has a 1-year low of $115.25 and a 1-year high of $177.00. The company has a market cap of $54.53 billion, a price-to-earnings ratio of 21.46, a price-to-earnings-growth ratio of 1.92 and a beta of 0.96. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The stock’s fifty day moving average price is $125.01 and its 200 day moving average price is $135.02.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.36 billion. During the same period last year, the business posted $1.40 earnings per share. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.6%. Zoetis’s payout ratio is presently 35.22%.

Wall Street Analyst Weigh In

Several research firms have recently commented on ZTS. The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a report on Monday, December 15th. KeyCorp assumed coverage on Zoetis in a research note on Thursday, November 20th. They issued a “sector weight” rating for the company. Piper Sandler restated a “neutral” rating and set a $135.00 price target (down previously from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Barclays initiated coverage on shares of Zoetis in a research note on Monday, December 8th. They set an “equal weight” rating and a $136.00 price objective for the company. Finally, BTIG Research restated a “buy” rating and set a $160.00 target price on shares of Zoetis in a research report on Wednesday, December 3rd. Five investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Zoetis presently has an average rating of “Hold” and a consensus target price of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.